S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

$26.58
-0.46 (-1.70%)
(As of 04/15/2024 ET)

Protagonist Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$36.00
35.44% Upside
High Forecast$38.00
Average Forecast$36.00
Low Forecast$32.00
TypeCurrent Forecast
4/16/23 to 4/15/24
1 Month Ago
3/17/23 to 3/16/24
3 Months Ago
1/16/23 to 1/16/24
1 Year Ago
4/16/22 to 4/16/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$36.00$36.00$35.25$35.50
Predicted Upside35.44% Upside58.49% Upside118.98% Upside107.71% Upside
Get Protagonist Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

PTGX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PTGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Protagonist Therapeutics Stock vs. The Competition

TypeProtagonist TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside35.29% Upside870.17% Upside10.31% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/28/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$34.00 ➝ $37.00+21.27%
2/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$38.00+28.42%
11/3/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Outperform ➝ Market Outperform$35.00 ➝ $37.00+121.82%
10/30/2023Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$32.00+127.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:57 PM ET.

PTGX Price Target - Frequently Asked Questions

What is Protagonist Therapeutics's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Protagonist Therapeutics stock is Buy based on the current 4 buy ratings for PTGX. The average twelve-month price prediction for Protagonist Therapeutics is $36.00 with a high price target of $38.00 and a low price target of $32.00. Learn more on PTGX's analyst rating history.

Do Wall Street analysts like Protagonist Therapeutics more than its competitors?

Analysts like Protagonist Therapeutics more than other Medical companies. The consensus rating for Protagonist Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how PTGX compares to other companies.

Does Protagonist Therapeutics's stock price have much upside?

According to analysts, Protagonist Therapeutics's stock has a predicted upside of 58.49% based on their 12-month stock forecasts.

What analysts cover Protagonist Therapeutics?

Protagonist Therapeutics has been rated by HC Wainwright, and JPMorgan Chase & Co. in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PTGX) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners